Dermapharm Holding SE (DE:DMP)
XETRA:DMP
Want to see DE:DMP full AI Analyst Report?
Total Valuation
Dermapharm Holding SE has a market cap or net worth of €2.45B. The enterprise value is €3.26B.
Market Cap€2.45B
Enterprise Value€3.26B
Share Statistics
Dermapharm Holding SE has 49,540,810 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding49,540,810
Owned by Insiders89.83%
Owned by Institutions―
Financial Efficiency
Dermapharm Holding SE’s return on equity (ROE) is 0.19 and return on invested capital (ROIC) is 7.97%.
Return on Equity (ROE)0.19
Return on Assets (ROA)0.06
Return on Invested Capital (ROIC)7.97%
Return on Capital Employed (ROCE)0.12
Revenue Per Employee322.71K
Profits Per Employee36.68K
Employee Count3,610
Asset Turnover0.53
Inventory Turnover2.35
Valuation Ratios
The current PE Ratio of Dermapharm Holding SE is 12.6. Dermapharm Holding SE’s PEG ratio is 0.96.
PE Ratio12.6
PS Ratio1.82
PB Ratio3.05
Price to Fair Value3.05
Price to FCF15.20
Price to Operating Cash Flow10.98
PEG Ratio0.96
Income Statement
In the last 12 months, Dermapharm Holding SE had revenue of 1.16B and earned 132.41M in profits. Earnings per share was 2.46.
Revenue1.16B
Gross Profit391.71M
Operating Income221.75M
Pretax Income183.51M
Net Income132.41M
EBITDA314.31M
Earnings Per Share (EPS)2.46
Cash Flow
In the last 12 months, operating cash flow was 242.22M and capital expenditures -43.89M, giving a free cash flow of 198.33M billion.
Operating Cash Flow242.22M
Free Cash Flow198.33M
Free Cash Flow per Share4.00
Dividends & Yields
Dermapharm Holding SE pays an annual dividend of €0.9, resulting in a dividend yield of 2.34%
Dividend Per Share€0.9
Dividend Yield2.34%
Payout Ratio41.86%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.48
52-Week Price Change41.66%
50-Day Moving Average45.06
200-Day Moving Average37.74
Relative Strength Index (RSI)60.97
Average Volume (3m)18.50K
Important Dates
Dermapharm Holding SE upcoming earnings date is Aug 25, 2026, TBA (Confirmed).
Last Earnings DateMay 13, 2026
Next Earnings DateAug 25, 2026
Ex-Dividend Date―
Financial Position
Dermapharm Holding SE as a current ratio of 2.05, with Debt / Equity ratio of 140.69%
Current Ratio2.05
Quick Ratio1.09
Debt to Market Cap0.49
Net Debt to EBITDA2.70
Interest Coverage Ratio4.21
Taxes
In the past 12 months, Dermapharm Holding SE has paid 52.16M in taxes.
Income Tax52.16M
Effective Tax Rate0.28
Enterprise Valuation
Dermapharm Holding SE EV to EBITDA ratio is 9.44, with an EV/FCF ratio of 21.29.
EV to Sales2.55
EV to EBITDA9.44
EV to Free Cash Flow21.29
EV to Operating Cash Flow16.35
Balance Sheet
Dermapharm Holding SE has €225.93M in cash and marketable securities with €1.04B in debt, giving a net cash position of -€813.53M billion.
Cash & Marketable Securities€225.93M
Total Debt€1.04B
Net Cash-€813.53M
Net Cash Per Share-€16.42
Tangible Book Value Per Share-€6.79
Margins
Gross margin is 42.74%, with operating margin of 19.03%, and net profit margin of 11.37%.
Gross Margin42.74%
Operating Margin19.03%
Pretax Margin15.75%
Net Profit Margin11.37%
EBITDA Margin26.98%
EBIT Margin19.03%
Analyst Forecast
The average price target for Dermapharm Holding SE is €47.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target€47.00
Price Target Upside1.73% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast-1.36%
EPS Growth Forecast39.24%